These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 4269352)

  • 21. [Antinuclear antibodies in localized scleroderma].
    Takehara K; Nakabayashi Y; Ishibashi Y; Moroi Y
    Nihon Hifuka Gakkai Zasshi; 1982; 92(8):883-8. PubMed ID: 6816966
    [No Abstract]   [Full Text] [Related]  

  • 22. Antibodies eluted from lymphoid cell membrane. Occurrence in certain varieties of scleroderma.
    Cormane RH; Hamerlinck F; Nunzi E
    Arch Dermatol; 1979 Jun; 115(6):709-12. PubMed ID: 453872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal immune deposits in scleroderma.
    McGiven AR; De Boer WG; Barnett AJ
    Pathology; 1971 Apr; 3(2):145-50. PubMed ID: 4937698
    [No Abstract]   [Full Text] [Related]  

  • 24. Autoantibodies to HMG-17 nucleosomal protein in patients with scleroderma.
    Vlachoyiannopoulos PG; Boumba VA; Tzioufas AG; Seferiadis C; Tsolas O; Moutsopoulos HM
    J Autoimmun; 1994 Apr; 7(2):193-201. PubMed ID: 8037838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Serum proteins in sclerodermia (author's transl)].
    Kobíková M; Fucíková T; Stáva Z
    Cesk Dermatol; 1980 Oct; 55(5):295-300. PubMed ID: 7261076
    [No Abstract]   [Full Text] [Related]  

  • 26. Circumscribed scleroderma with immunologic evidence of systemic lupus erythematosus.
    Mitchell AJ; Rusin LJ; Diaz LA
    Arch Dermatol; 1980 Jan; 116(1):69-73. PubMed ID: 6153258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Scleroderma. Which tests should be performed?].
    Crickx B; Lazareth I
    Ann Dermatol Venereol; 1990; 117(1):83-6. PubMed ID: 2181910
    [No Abstract]   [Full Text] [Related]  

  • 28. [Demonstration of antinuclear antibodies in the epidermis of patients with progressive systemic sclerosis, generalized lupus erythematosus and dermatomyositis].
    Lamas Robles C; Mejía Arreguín S; Orozco Medina JH; González Mendoza A
    Rev Invest Clin; 1984; 36(2):115-9. PubMed ID: 6385174
    [No Abstract]   [Full Text] [Related]  

  • 29. Anti-U3 snRNP antibodies in localised scleroderma.
    Yimane K; Ihn H; Kubo M; Asano Y; Yazawa N; Tamaki K
    Ann Rheum Dis; 2001 Dec; 60(12):1157-8. PubMed ID: 11760725
    [No Abstract]   [Full Text] [Related]  

  • 30. [Immunofluorescent method in dermatology (review of the literature)].
    Dobzhanskiĭ SI; Tabakova LS
    Vestn Dermatol Venerol; 1974 Aug; 0(8):13-8. PubMed ID: 4611090
    [No Abstract]   [Full Text] [Related]  

  • 31. [Serum antinuclear antibodies (in patients with visceral erythematodes, rheumatoid arthritis, progressive systemic sclerosis and discoid erythematodes)].
    Horvat Z
    Acta Med Iugosl; 1970; 24(3):229-40. PubMed ID: 4928076
    [No Abstract]   [Full Text] [Related]  

  • 32. Antinuclear antibodies as immunologic markers for a benign subset and different clinical characteristics of scleroderma.
    Kleinsmith DM; Heinzerling RH; Burnham TK
    Arch Dermatol; 1982 Nov; 118(11):882-5. PubMed ID: 6753766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antinuclear antibody profile in progressive systemic sclerosis. A multicenter study].
    Martínez-Cordero E; Burgos-Vargas R; Herrera-Esparza R; Reyes PA
    Rev Invest Clin; 1983; 35(4):273-7. PubMed ID: 6369466
    [No Abstract]   [Full Text] [Related]  

  • 34. Antinuclear antibodies: their significance in scleroderma.
    Jordon RE; Deheer D; Schroeter A; Winkelmann RK
    Mayo Clin Proc; 1971 Feb; 46(2):111-3. PubMed ID: 4925983
    [No Abstract]   [Full Text] [Related]  

  • 35. [Antinuclear antibodies and beta1A concentration in systemic lupus erythematosus and other diseases].
    Monegat JN; Joller-Jemelka HI; Grob PJ
    Schweiz Med Wochenschr; 1974 Nov; 104(45):1614-23. PubMed ID: 4612703
    [No Abstract]   [Full Text] [Related]  

  • 36. Antinucleosome antibody is a major autoantibody in localized scleroderma.
    Sato S; Kodera M; Hasegawa M; Fujimoto M; Takehara K
    Br J Dermatol; 2004 Dec; 151(6):1182-8. PubMed ID: 15606513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antinuclear antibodies, complement and circulating immune complexes in scleroderma].
    Cárdenas Ortega A; Mejía Arregui S; Orozco Medina H; Arroyave CM
    Alergia; 1981 Jul; 28(3):111-20. PubMed ID: 7036785
    [No Abstract]   [Full Text] [Related]  

  • 38. [Importance of certain laboratory indicators for determination of the activity of systemic scleroderma].
    Shiapak EA; Drampian FS; Kessel' VP; Aznaurian AV; Lobanova IN
    Zh Eksp Klin Med; 1973; 13(3):96-100. PubMed ID: 4599068
    [No Abstract]   [Full Text] [Related]  

  • 39. [Types of anticellular structure antisera in scleroderma patients].
    Ni ZM
    Zhonghua Yi Xue Za Zhi; 1993 May; 73(5):270-2, 318. PubMed ID: 8221243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Progressive scleroderma and the terminal stage of malignant hypertension].
    Schäfer HE; Schäfer A
    Arch Klin Med; 1968; 214(3):187-200. PubMed ID: 4879138
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.